VARIABLE BIOAVAILABILITY FOLLOWING REPEATED ORAL DOSES OF ETOPOSIDE

被引：64
作者：
HARVEY, VJ
SLEVIN, ML
JOEL, SP
SMYTHE, MM
JOHNSTON, A
WRIGLEY, PFM
机构：
[1] ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND
[2] HACKNEY HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON,ENGLAND
[3] ST BARTHOLOMEWS HOSP,DEPT CLIN PHARMACOL,LONDON EC1A 7BE,ENGLAND
来源：
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1985年 / 21卷 / 11期
关键词：
D O I：
10.1016/0277-5379(85)90310-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1315 / 1319
页数：5
相关论文
共 29 条
[1]   COMPARISON OF HUMAN PHARMACOKINETICS OF VM-26 AND VP-16, 2 ANTINEOPLASTIC EPIPODOPHYLLOTOXIN GLUCOPYRANOSIDE DERIVATIVES [J].
ALLEN, LM ;
CREAVEN, PJ .
EUROPEAN JOURNAL OF CANCER, 1975, 11 (10) :697-707
[2]  
ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71
[3]  
BEVERIDGE T, 1976, BIOAVAILABILITY STUD
[4]  
CAVALLI F, 1978, CANCER TREAT REP, V62, P473
[5]   EFFECT OF POSTURE AND DRINK VOLUME ON THE SWALLOWING OF CAPSULES [J].
CHANNER, KS ;
VIRJEE, J .
BRITISH MEDICAL JOURNAL, 1982, 285 (6356) :1702-1702
[6]   SMALL CELL-CARCINOMA OF THE LUNG [J].
COMIS, RL .
CANCER TREATMENT REVIEWS, 1982, 9 (03) :237-258
[7]  
CREAVEN PJ, 1975, CLIN PHARMACOL THER, V18, P221
[8]  
DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141
[9]  
DOMBERNOWSKY P, 1973, ACTA PATH MICRO IM A, VA 81, P715
[10]   ETOPOSIDE AS SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY OF BRONCHOGENIC-CARCINOMA [J].
GOLDHIRSCH, A ;
JOSS, R ;
CAVALLI, F ;
BRUNNER, KW .
CANCER TREATMENT REVIEWS, 1982, 9 :85-90
123